Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.66
+0.50 (6.98%)
At close: Apr 30, 2026, 4:00 PM EDT
7.68
+0.02 (0.26%)
After-hours: Apr 30, 2026, 4:04 PM EDT
Unicycive Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
193.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 675.00K | -276.00K | -29.02% |
| Dec 31, 2022 | 951.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Protalix BioTherapeutics | 52.74M |
| Precision BioSciences | 34.26M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 2.04M |
UNCY News
- 21 days ago - Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 3 months ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 3 months ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 4 months ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 5 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp